MXPA00011248A - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.

Info

Publication number
MXPA00011248A
MXPA00011248A MXPA00011248A MXPA00011248A MXPA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A
Authority
MX
Mexico
Prior art keywords
radiation
receptor tyrosine
inhibitors
treatment
growth factor
Prior art date
Application number
MXPA00011248A
Other languages
Spanish (es)
Inventor
Harlan W Waksal
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of MXPA00011248A publication Critical patent/MXPA00011248A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis.
MXPA00011248A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. MXPA00011248A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US20613898A 1998-12-07 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
MXPA00011248A true MXPA00011248A (en) 2004-09-06

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00011248A MXPA00011248A (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.

Country Status (14)

Country Link
EP (1) EP1080113A4 (en)
JP (1) JP2002515511A (en)
KR (1) KR20010071271A (en)
CN (1) CN1314917A (en)
AU (1) AU4079999A (en)
BR (1) BR9910511A (en)
CA (1) CA2332331A1 (en)
CZ (1) CZ20004224A3 (en)
HK (1) HK1040720A1 (en)
IL (1) IL139707A0 (en)
MX (1) MXPA00011248A (en)
PL (1) PL348634A1 (en)
SK (1) SK17282000A3 (en)
WO (1) WO1999060023A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
EP1206234A4 (en) 1999-06-03 2005-06-01 Jessie L S Au Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CU22979A1 (en) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1916001B1 (en) 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
KR100968657B1 (en) * 2002-04-02 2010-07-06 네르비아노 메디칼 사이언시스 에스.알.엘. Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy
KR101086533B1 (en) 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
JP2007535895A (en) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド Fully human antibody against human insulin-like growth factor-1 receptor
JP2007500248A (en) 2003-06-09 2007-01-11 ワクサル，サムエル Method for inhibiting receptor tyrosine kinase by extracellular antagonist and intracellular antagonist
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2005016967A2 (en) 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
ATE514783T1 (en) 2003-11-12 2011-07-15 Schering Corp PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
RU2006146612A (en) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) TREATMENT OF EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR AND CISPLATIN AND INHIBITOR
MX2007006640A (en) 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP2100614B8 (en) 2005-06-17 2013-11-20 ImClone LLC Antibody against PDGFR-alpha for use in the treatment of tumours
JP5055284B2 (en) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (en) 2006-08-21 2012-10-15 Hoffmann La Roche TUMOR THERAPY WITH ANTI-VEGF ANTIBODY
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
MX2009010611A (en) * 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
US20110243931A1 (en) 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
UA104868C2 (en) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Method for treating patient having neoplastic tumor according to predicted reaction
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
RU2012109451A (en) 2009-08-14 2013-09-27 Роше Гликарт Аг COMBINED THERAPY BASED ON AFUCHOSILY ANTIBODY TO CD20 IN COMBINATION WITH FLUDARABIN AND / OR MITOXANTRON
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
BR112013014522A2 (en) 2010-12-16 2017-09-26 Roche Glycart Ag afucosylated anti-cd20 antibody and its use, composition and method for treating a cancer patient
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2831957A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
EP2817340B1 (en) * 2012-02-23 2020-12-09 Daiichi Sankyo Europe GmbH Her3 inhibitor for modulating radiosensitivity
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014039855A1 (en) 2012-09-07 2014-03-13 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945A (en) 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 Combination therapy of an anti-HER 2 antibody-drug conjugate and a Bcl-2 inhibitor
KR20180100125A (en) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. MAT2A inhibitor for treating MTAP null cancer
WO2017125429A1 (en) 2016-01-18 2017-07-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
CN110869391A (en) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 Combination therapy with BET inhibitors, Bcl-2 inhibitors and anti-CD 20 antibodies
EP3658188A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
US20200354460A1 (en) * 2017-09-29 2020-11-12 Wuxi Biologics Ireland Limited. Bispecific antibodies against EGFR and PD-1
CN111989092A (en) 2018-04-18 2020-11-24 豪夫迈·罗氏有限公司 Combination therapy of BET inhibitors and proteasome inhibitors
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0831880A4 (en) * 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
CZ20004224A3 (en) 2002-02-13
BR9910511A (en) 2001-11-20
SK17282000A3 (en) 2002-04-04
HK1040720A1 (en) 2002-06-21
EP1080113A1 (en) 2001-03-07
CN1314917A (en) 2001-09-26
CA2332331A1 (en) 1999-11-25
JP2002515511A (en) 2002-05-28
KR20010071271A (en) 2001-07-28
WO1999060023A1 (en) 1999-11-25
PL348634A1 (en) 2002-06-03
AU4079999A (en) 1999-12-06
IL139707A0 (en) 2002-02-10
EP1080113A4 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
MXPA00011248A (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
ATE339957T1 (en) USE OF EGFR TYROSINE KINASE INHIBITORS TO TREAT BREAST CANCER
US5919813C1 (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
EP2042194A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
HUS1700048I1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
TR200201442T2 (en) Preparation and use of radium-223 for calcified target tissues for pain relief, bone cancer therapy, and keeping bone surface healthy.
MD1616G2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
DE69506561T2 (en) IMMUNO-CONJUGATES CONTAIN TYROSINE KINASE INHIBITORS
MD1632G2 (en) Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
GR20010300033T1 (en) Raf kinase inhibitors
FI972492A0 (en) Imidazole derivatives as inhibitors of protein kinases, in particular EGF-R tyrosine kinase
MX9700118A (en) Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin.
MY130363A (en) "pyrrole substituted 2-indolinone protein kinase inhibitors"
HK1035188A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
MY133403A (en) Tetracycline derivatives and methods of use thereof
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
DK0912192T3 (en) Administration of GM-CSF to treat brain tumors and prevent the recurrence of such tumors
TNSN04015A1 (en) Combination therapy for the treatment of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
GB2370961B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
GB9824437D0 (en) Gene therapy
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers